Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began

New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.

Machinery cogwheels, industry concept
The coronavirus outbreak forced changes to FDA workflow and priorities, which may have affected NDA-BLA approval output. • Source: Shutterstock

The US Food and Drug Administration's generic drugs program output has flourished since the coronavirus pandemic forced workflow alterations, while the new drugs program has suffered.

A seven-day stretch when the agency transitioned to mass telework corresponded with the slowdown in approval output in the Office...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet